Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection by Csajka Chantal, Marzolini Catia, Fattinger Karin, Décosterd Laurent A, Fellay Jacques, Telenti Amalio, Biollaz Jérôme, Buclin Thierry in Clinical pharmacology and therapeutics (2003). PubMed

Abstract

The reverse transcriptase inhibitor efavirenz is currently used at a fixed dose of 600 mg/d. However, dosage individualization based on plasma concentration monitoring might be indicated. This study aimed to assess the efavirenz pharmacokinetic profile and interpatient versus intrapatient variability in patients who are positive for human immunodeficiency virus, to explore the relationship between drug exposure, efficacy, and central nervous system toxicity and to build up a Bayesian approach for dosage adaptation.

[ hide abstract ]

Discussed In Paper

Variant Annotations

Sign in to see variant annotations.